CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the potential of two new drugs, glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors, to protect against acute kidney injury in intensive care unit patients. It employs advanced measurement techniques to understand their renoprotective mechanisms and aims…
On the intensive care unit, more than 50% of patients have acute kidney injury, and these patients suffer higher mortality and long-term morbidity.
To date, no specific therapies exist to prevent or treat acute kidney injury on the intensive care unit.
We now have two new endocrinologic agents, glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors, able to protect patients with diabetes from chronic kidney disease.
The objective of this action is to investig…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Australia, Parkville
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
